Please enable Javascript
Leah Sherwood
Articles by Leah Sherwood
September 2023
This issue includes a Get to Know with Catherine Coombs, MD; a debate on time-limited frontline therapy in CLL, and more.
Read More
FDA Approves Momelotinib in Patients with Myelofibrosis with Anemia
Leah Sherwood
Myelofibrosis
|
September 16, 2023
Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease.
Read More
Phillip Scheinberg, MD, Reports on MDS From the Eleventh Annual SOHO Meeting
Phillip Scheinberg, MD
Myelodysplastic Syndromes
|
September 8, 2023
"There's been a lot of focus on classifications and mutations: they're coming with a lot of force," Dr. Scheinberg said.
View More
ENHANCE-3 Testing Magrolimab-Based Triplet in Untreated, Unfit AML
Leah Sherwood
Acute Myeloid Leukemia
|
September 8, 2023
Enrolled patients must be aged 75 years or older or aged 18-74 years with specific comorbidities.
Read More
ENHANCE-2: Testing Magrolimab Combo in TP53-Mutated AML
Leah Sherwood
Meeting News
|
September 8, 2023
The trial will enroll approximately 346 patients with treatment-naive TP53-mutated disease or biallelic 17p deletions.
Read More
Elias Jabbour, MD, on the Phase III PhALLCON Trial in Ph+ ALL
Elias Jabbour, MD
Acute Lymphoblastic Leukemia
|
September 7, 2023
Dr. Jabbour presented data from the study at the Eleventh Annual Meeting of SOHO.
View More
SOHO President Kicks Off Annual Meeting with Opening Remarks
Cecilia Brown
Meeting News
|
September 6, 2023
The Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO) began on Wednesday.
Read More
July/August 2023
This issue includes BCT Editorial Board highlights, a Get to Know with John DiPersio, MD, PhD; a feature on ctDNA; and more.
Read More
FDA Grants Fast Track Designation to Selinexor in Myelofibrosis Treatment
Leah Sherwood
Myelofibrosis
|
August 9, 2023
In June 2023, the manufacturer of the drug initiated XPORT-MF-034, a pivotal phase III clinical trial.
Read More
Regulatory Agencies Approve IND Applications for LBL-034 in Multiple Myeloma
Leah Sherwood
Myeloma
|
August 2, 2023
The US FDA and NMPA have approved IND applications for LBL-034 for the treatment of relapsed or refractory multiple myeloma.
Read More
FMT Safe But Not Statistically Significant in Reducing Infections in AML, Allogeneic HSCT
Leah Sherwood
Acute Myeloid Leukemia
|
July 28, 2023
The difference in infection rates between the treatment and placebo groups was not statistically significant.
Read More
Positive Opinion Issued for JZP458
Leah Sherwood
Acute Lymphoblastic Leukemia
|
July 26, 2023
EMA CHMP adopted a positive opinion recommending the marketing authorization of JZP458.
Read More
Triplet Chemotherapy-Free Therapy ‘Significantly Improved Outcomes’ Across All MCL Risk Groups
Leah Sherwood
Mantle Cell Lymphoma
|
July 24, 2023
With a median follow up of 41 months, the three-year PFS and OS rates were 85% and 86%, respectively.
Read More
Phase II Trial Supports Frontline Acalabrutinib Plus Rituximab in Older Patients with MCL
Leah Sherwood
Mantle Cell Lymphoma
|
July 24, 2023
The single-arm, phase II clinical trial enrolled 50 previously untreated patients with a median age of 69 years.
Read More
MRD-Driven Strategy Yields Promising Outcomes in Indolent MCL
Leah Sherwood
Mantle Cell Lymphoma
|
July 23, 2023
The trial assessed discontinuation of ibrutinib treatment in patients with indolent clinical forms of MCL.
Read More
SOHO Ambassador Program Strengthens Global HemOnc Community
Leah Sherwood
Acute Myeloid Leukemia
|
July 17, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Read More
What Is the Future of CART-ddBCMA?
Shambavi Richard, MD
Myeloma
|
July 17, 2023
In June 2023, a patient death led to the US Food and Drug Administration pausing the iMMagine-1 study.
View More
FDA Clears IND Application for P-CD19CD20-ALLO1
Leah Sherwood
Aggressive B-Cell Lymphoma
|
July 12, 2023
The CAR-T targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies.
Read More
What Is the Future of Flow Cytometry in Lymphoma Diagnostics?
Leah Sherwood
Hodgkin Lymphoma
|
July 10, 2023
In this video interview, Dr. Mats Ehinger discusses the future of flow cytometry in lymphoma diagnostics.
View More
FDA Removes Partial Clinical Hold From TakeAim Leukemia Study
Leah Sherwood
Myelodysplastic Syndromes
|
July 7, 2023
The FDA has removed the partial clinical hold on the TakeAim Leukemia phase I/II study of emavusertib.
Read More
Load More